Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 10/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070768 | 0.91 | LMNA (0.50) | F9LMNAF10F2PRSS1 | |
| SCHEMBL2073671 | 0.90 | F9 (0.44) | F9LMNAF10F2PRSS1 | |
| SCHEMBL2073976 | 0.89 | F10 (0.45) | F9LMNAF10F2PRSS1 | |
| SCHEMBL2070569 | 0.89 | F10 (0.45) | F9LMNAF10F2PRSS1 | |
| SCHEMBL2070983 | 0.89 | F10 (0.45) | F9LMNAF10F2PRSS1 | |
| SCHEMBL2073145 | 0.81 | F9 (0.45) | F9F10F2PRSS1PRSS2 | |
| SCHEMBL2072384 | 0.80 | LMNA (0.45) | F9LMNA | |
| SCHEMBL2072554 | 0.79 | LMNA (0.39) | F9LMNA | |
| SCHEMBL2072039 | 0.79 | F10 (0.38) | F9LMNAF10CIT | |
| SCHEMBL2073134 | 0.79 | F10 (0.48) | F9LMNAF10CITKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | claimed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | claimed |
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | MERCK PATENTGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | claimed |
| EP-1414456-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GmbH (DE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003013531-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | claimed |
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | MERCK PATENTGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1414456-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003013531-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | F11, F2, F12 | F9 7/4885LMNA 1128/4885F10 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.